Get the Daily Brief
Latest Biotech News
Tubulis smashes European Series C record — €308m to expand ADC program
Tubulis GmbH closed an oversubscribed €308 million (≈$356 million) Series C to accelerate clinical development of its lead antibody‑drug conjugate (TUB‑040) and broaden earlier‑line indications....
Illumina’s Constellation mapped‑read pilot finds hard‑to‑see variants — ASHG data
At ASHG, pilot data from GeneDx using Illumina’s Constellation mapped‑read technology showed improved detection of variants in genomic regions historically challenging for short reads, including...
Plasmidsaurus rolls out ultrafast RNA‑Seq — three‑day turnaround for expression data
Plasmidsaurus launched an ultrafast RNA‑Seq service for Illumina short‑read workflows promising sample‑to‑analyzed‑data in as little as three days and simplified inputs (crude cell preps,...
Genomics Ltd debuts Mystra AI platform — automated target and biomarker evidence
Genomics Ltd introduced Mystra, an AI‑enabled genomics platform designed to accelerate drug‑target and biomarker discovery by integrating roughly 20,000 GWAS datasets and applying machine‑learning...
Lonza gets Swissmedic sign‑off for high‑potency biologics filling line in Stein
Lonza announced Swissmedic approval and GMP licensing for a new aseptic drug‑product filling line in Stein, Switzerland, configured for highly potent biologics including ADCs and other modalities...
Waters debuts charge‑detection MS — rapid AAV and biotherapeutic characterization
Waters launched a charge‑detection mass spectrometry platform aimed at accelerating analyses of protein complexes, nucleic acids and gene‑delivery vehicles, with a particular emphasis on rapid AAV...
Praxis’ late-stage gamble pays off — ulixacaltamide clears two Phase 3 tests
Praxis Precision Medicines reported that ulixacaltamide met primary endpoints in two Phase 3 trials, delivering a decisive clinical win for an essential tremor therapy. The company said treated...
Kite doubles down on in‑vivo CAR‑T: China tie-up with Pregene
Gilead’s Kite Pharma struck a partnership with Shenzhen-based Pregene Biopharma to accelerate in vivo CAR‑T and next‑generation cell therapies, paying an initial upfront fee and structuring...
Novo Nordisk bets big on complement biology — Omeros’ MASP‑3 asset acquired
Novo Nordisk agreed to acquire global rights to Omeros’ MASP‑3 inhibitor zaltenibart, paying near‑term upfront and milestone sums and reserving up to $2.1 billion in total consideration tied to...
Tubulis breaks European ADC record — massive Series C to fuel clinic push
German ADC specialist Tubulis closed a landmark Series C financing — roughly €308 million (~$356 million) — to accelerate clinical development of its lead ADC, TUB‑040, and expand programs into...
Adcytherix secures Series A to push ADC candidate to clinic
French antibody specialist Adcytherix closed a sizable Series A (reported at about €105 million / US$122 million) to advance its lead antibody‑drug conjugate into first‑in‑human studies. The...
Plasmidsaurus launches ultrafast RNA‑Seq — three‑day transcriptomics service
Plasmidsaurus introduced an ultrafast RNA‑Seq service for Illumina short‑read workflows, promising turnaround in as little as three days and simplified sample logistics for cell‑based experiments....
Genomics Ltd unveils Mystra — AI platform for target and biomarker de‑risking
UK‑based Genomics Ltd. launched Mystra, an AI‑enabled genomics platform designed to accelerate target and biomarker discovery by integrating roughly 20,000 GWAS datasets. The company said Mystra...
Illumina’s constellation mapped‑read tech shows early wins with GeneDx pilot
Illumina presented pilot data from a GeneDx collaboration showing its Constellation mapped‑read technology can detect variants that elude traditional short‑read methods, including repeat...
Generative AI powers biology: KAIST and Google models propose testable drug‑response strategies
Two AI advances showcased at recent conferences highlight how generative models are being applied to biological discovery. KAIST researchers unveiled a generative AI that predicts and assembles...
DeepSomatic and CASTLE benchmarks advance somatic variant calling across platforms
A pair of Nature Biotechnology reports introduced DeepSomatic, a deep‑learning somatic small‑variant caller compatible with short‑ and long‑read sequencing, and a set of public CASTLE benchmark...
Praxis wins two Phase 3 trials — NDA talk begins
Praxis Precision Medicines reported that ulixacaltamide met the primary endpoints in two pivotal Phase 3 trials for essential tremor, positioning the oral small-molecule T‑type calcium channel...
Kite and Pregene tie up for in vivo CAR‑T development — big payments on table
Gilead’s Kite Pharma struck a multi-partner collaboration with Chinese biotech Pregene Biopharma to accelerate in vivo CAR‑T and related next‑generation cell therapies, with the agreement carrying...
Novo Nordisk buys Omeros’ MASP‑3 candidate — $2.1B upside
Novo Nordisk agreed to acquire global rights to zaltenibart (OMS‑906), an antibody that inhibits MASP‑3 in the complement pathway, from Omeros in a deal valued at up to $2.1 billion including...
Tubulis secures record ADC Series C — clinical expansion funded
German ADC specialist Tubulis closed an oversubscribed Series C round—one of the largest European private raises this year—to accelerate clinical development of its lead antibody‑drug conjugate...